If future animal models prove to demonstrate neuroprotective effects, Ianthellamide A will not only be used to model novel KMO inhibitors, but could also possibly serve as therapy for the treatment of neurodegenerative diseases. This evidence concerns the gene KMO and neurodegenerative disease.